Platelet inhibition by adjunctive cilostazol versus high maintenance-dose clopidogrel in patients with acute myocardial infarction according to cytochrome P450 2C19 genotype

JACC: Cardiovascular Interventions

Volumn 4, Issue 4, 2011, Pages 381-391

  Kim, In Suk ^a   Jeong, Young Hoon ^a   Park, Yongwhi ^a   Park, Ki Soo ^a   Yun, Seong Eun ^a   Park, Jeong Rang ^a   Hwang, Seok Jae ^a   Koh, Eun Ha ^a   Kwak, Choong Hwan ^a   Hwang, Jin Yong ^a   Kim, Sunjoo ^a  

^a Gyeongsang National University   (South Korea)

Author keywords

acute myocardial infarction; adjunctive cilostazol; CYP2C19 polymorphism; high maintenance dose clopidogrel; platelet

Indexed keywords

ADENOSINE DIPHOSPHATE; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CILOSTAZOL; CLOPIDOGREL; CYTOCHROME P450 2C19; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; NITRATE; PROTON PUMP INHIBITOR;

ACUTE HEART INFARCTION; ADULT; ALLELE; ARTICLE; FEMALE; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SINGLE NUCLEOTIDE POLYMORPHISM; THROMBOCYTE AGGREGATION; THROMBOCYTE FUNCTION;

ADENOSINE DIPHOSPHATE; AGED; ANGIOPLASTY, BALLOON, CORONARY; ARYL HYDROCARBON HYDROXYLASES; ASPIRIN; CHI-SQUARE DISTRIBUTION; DRUG THERAPY, COMBINATION; FEMALE; GENOTYPE; HUMANS; KOREA; LIVER; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PHENOTYPE; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; PLATELET FUNCTION TESTS; PREDICTIVE VALUE OF TESTS; REGRESSION ANALYSIS; RISK ASSESSMENT; RISK FACTORS; TETRAZOLES; THROMBOSIS; TICLOPIDINE; TREATMENT OUTCOME;

EID: 79955093619     PISSN: 19368798     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jcin.2010.12.010     Document Type: Article

References (38)

1. S. Matetzky, B. Shenkman, and V. Guetta Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction Circulation 109 2004 3171 3175
2. T. Cuisset, C. Frere, and J. Quilici High post-treatment platelet reactivity identified low-responders to dual antiplatelet therapy at increased risk of recurrent cardiovascular events after stenting for acute coronary syndrome J Thromb Haemost 4 2006 542 549
3. D.R. Holmes Jr., G.J. Dehmer, S. Kaul, D. Leifer, P.T. O'Gara, and C.M. Stein ACCF/AHA clopidogrel clinical alert: approaches to the FDA "boxed warning": a report of the American College of Cardiology Foundation Task Force on clinical expert consensus documents and the American Heart Association endorsed by the Society for Cardiovascular Angiography and Interventions and the Society of Thoracic Surgeons J Am Coll Cardiol 56 2010 321 341
4. J.L. Mega, S.L. Close, and S.D. Wiviott Cytochrome p-450 polymorphisms and response to clopidogrel N Engl J Med 360 2009 354 362
5. T. Simon, C. Verstuyft, M. Mary-Krause FAST-MI Investigators Genetic determinants of response to clopidogrel and cardiovascular events N Engl J Med 360 2009 363 375
6. Y.H. Jeong, J.Y. Hwang, and I.S. Kim Adding cilostazol to dual antiplatelet therapy achieves greater platelet inhibition than high maintenance dose clopidogrel in patients with acute myocardial infarction: results of the Adjunctive Cilostazol versus High Maintenance Dose Clopidogrel in Patients with AMI (ACCEL-AMI) study Circ Cardiovasc Interv 3 2010 17 26
7. Y. Han, Y. Li, and S. Wang Cilostazol in addition to aspirin and clopidogrel improves long-term outcomes after percutaneous coronary intervention in patients with acute coronary syndromes: a randomized, controlled study Am Heart J 157 2009 733 739
8. K.Y. Chen, S.W. Rha, Y.J. Li Korea Acute Myocardial Infarction Registry Investigators Triple versus dual antiplatelet therapy in patients with acute ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention Circulation 119 2009 3207 3214
9. S.W. Lee, S.W. Park, and S.C. Yun Triple antiplatelet therapy reduces ischemic events after drug-eluting stent implantation: Drug-Eluting stenting followed by Cilostazol treatment REduces Adverse serious Cardiac Events (DECREASE registry) Am Heart J 159 2010 28491.e1
10. S.W. Lee, S.W. Park, and M.K. Hong Triple versus dual antiplatelet therapy after coronary stenting: impact on stent thrombosis J Am Coll Cardiol 46 2005 1833 1837
11. M. Hiratsuka, Y. Hinai, and T. Sasaki Characterization of human cytochrome p450 enzymes involved in the metabolism of cilostazol Drug Metab Dispos 35 2007 1730 1732 (Pubitemid 47481597)
12. H. Fukushima-Uesaka, Y. Saito, and K. Maekawa Genetic variations and haplotypes of CYP2C19 in a Japanese population Drug Metab Pharmacokinet 20 2005 300 307
13. M. Garcia-Barcel, L.Y. Chow, and H.F. Kum-Chiu Frequencies of defective CYP2C19 alleles in a Hong Kong Chinese population: detection of the rare allele CYP2C19 (*) 4 Clin Chem 45 1999 2273 2274
14. 12 assay J Thromb Thrombolysis 30 2010 486 495
15. M.J. Price, S. Endemann, and R.R. Gollapudi Prognostic significance of post-clopidogrel platelet reactivity assessed by a point-of-care assay on thrombotic events after drug-eluting stent implantation Eur Heart J 29 2008 992 1000 (Pubitemid 351844676)
16. L. Bonello, U.S. Tantry, R. Marcucci Working Group on High On-Treatment Platelet Reactivity Consensus and future directions on the definition of high on-treatment platelet reactivity to adenosine diphosphate J Am Coll Cardiol 56 2010 919 933
17. P.A. Gurbel, M.J. Antonino, and K.P. Bliden Platelet reactivity to adenosine diphosphate and long-term ischemic event occurrence following percutaneous coronary intervention: a potential antiplatelet therapeutic target Platelets 19 2008 595 604
18. H. Fukushima-Uesaka, Y. Saito, and K. Maekawa Genetic variations and haplotypes of CYP2C19 in a Japanese population Drug Metab Pharmacokinet 20 2005 300 307
19. Y.H. Jeong, I.S. Kim, and Y. Park Carriage of cytochrome 2C19 polymorphism is associated with risk of high post-treatment platelet reactivity on high maintenance-dose clopidogrel of 150 mg/day: results of the ACCEL-DOUBLE (Accelerated Platelet Inhibition by a Double Dose of Clopidogrel According to Gene Polymorphism) study J Am Coll Cardiol Intv 3 2010 731 741
20. T.F. Lscher, J. Steffel, and F.R. Eberli Drug-eluting stent and coronary thrombosis: biological mechanisms and clinical implications Circulation 115 2007 1051 1058 (Pubitemid 46328299)
21. L. Wallentin, R.C. Becker, A. Budaj PLATO Investigators Ticagrelor versus clopidogrel in patients with acute coronary syndromes N Engl J Med 361 2009 1045 1057
22. S.D. Wiviott, E. Braunwald, C.H. McCabe TRITONTIMI Investigators Prasugrel versus clopidogrel in patients with acute coronary syndromes N Engl J Med 357 2007 2001 2015 (Pubitemid 350106708)
23. S.R. Mehta, J.P. Bassand, S. Chrolavicius CURRENTOASIS 7 Investigators Dose comparisons of clopidogrel and aspirin in acute coronary syndromes N Engl J Med 363 2010 930 942
24. T. Cuisset, G. Cayla, and C. Frere Predictive value of post-treatment platelet reactivity for occurrence of post-discharge bleeding after non-ST elevation acute coronary syndrome Shifting from antiplatelet resistance to bleeding risk assessment? EuroIntervention 5 2009 325 329
25. D. Sibbing, S. Schulz, and S. Braun Antiplatelet effects of clopidogrel and bleeding in patients undergoing coronary stent placement J Thromb Haemost 8 2010 250 256
26. H. Ota, M. Eto, and J. Ako Sirolimus and everolimus induce endothelial cellular senescence via sirtuin 1 down-regulation: therapeutic implication of cilostazol after drug-eluting stent implantation J Am Coll Cardiol 53 2009 2298 2305
27. S. Goto Cilostazol: potential mechanism of action for antithrombotic effects accompanied by a low rate of bleeding Atheroscler Suppl 6 2005 3 11 (Pubitemid 43263084)
28. A.J. Comerota Effect on platelet function of cilostazol, clopidogrel, and aspirin, each alone or in combination Atheroscler Suppl 6 2006 13 19
29. A.Y. Shen, J.F. Yao, S.S. Brar, M.B. Jorgensen, and W. Chen Racial/ethnic differences in the risk of intracranial hemorrhage among patients with atrial fibrillation J Am Coll Cardiol 50 2007 309 315 (Pubitemid 47061504)
30. K.H. Mak, D.L. Bhatt, and M. Shao Ethnic variation in adverse cardiovascular outcomes and bleeding complications in the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) study Am Heart J 157 2009 658 665
31. V.L. Serebruany, and D. Atar The PLATO trial: do you believe in magic? Eur Heart J 31 2010 764 767
32. S. Manickavasagam, Y. Ye, and Y. Lin The cardioprotective effect of a statin and cilostazol combination: relationship to Akt and endothelial nitric oxide synthase activation Cardiovasc Drugs Ther 21 2007 321 330 (Pubitemid 47598922)
33. Y. Hattori, K. Suzuki, and A. Tomizawa Cilostazol inhibits cytokine-induced nuclear factor-kappaB activation via AMP-activated protein kinase activation in vascular endothelial cells Cardiovasc Res 81 2009 133 139
34. S.W. Lee, S.W. Park, and Y.H. Kim Drug-eluting stenting followed by cilostazol treatment reduces late restenosis in patients with diabetes mellitus the DECLARE-DIABETES trial (A Randomized Comparison of Triple Antiplatelet Therapy with Dual Antiplatelet Therapy After Drug-Eluting Stent Implantation in Diabetic Patients) J Am Coll Cardiol 51 2008 1181 1187
35. M.J. Price, P.B. Berger, and P.S. Teirstein Standard vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial JAMA 305 2011 1097 1105
36. L. Bonello, S. Armero, and O. Ait-Mokhtar Clopidogrel loading dose adjustment according to platelet reactivity monitoring in patients carrying the 2C19 (*)2 loss of function polymorphism J Am Coll Cardiol 56 2010 1630 1636
37. J.W. Suh, S.P. Lee, and K.W. Park Multicenter randomized trial evaluating the efficacy of cilostazol on ischemic vascular complications after drug-eluting stent implantation for coronary heart disease: results of the CILON-T (influence of CILostazol-based triple antiplatelet therapy ON ischemic complication after drug-eluting stenT implantation) trial J Am Coll Cardiol 57 2011 280 289
38. G. Montalescot, G. Sideris, C. Meuleman ALBION Trial Investigators A randomized comparison of high clopidogrel loading doses in patients with non-ST-segment elevation acute coronary syndromes: the ALBION (Assessment of the Best Loading Dose of Clopidogrel to Blunt Platelet Activation, Inflammation and Ongoing Necrosis) trial J Am Coll Cardiol 48 2006 931 938 (Pubitemid 44292463)